Weight-loss drugs such as semaglutide are effective at tackling the biological drivers of Alzheimer’s disease, a new study ...

This continuing education course details the role of GLP-1 injectables in managing chronic conditions and overweight/obesity, ...

Here’s what researchers want you to know.

As of April 2026, more than 40 million GLP-1 receptor agonist prescriptions are dispensed annually in the United States alone, driven by blockbuster drugs like Ozempic (semaglutide) and Mounjaro ...

The emergence of peptide therapeutics marks a transformative shift in the types of products being developed and manufactured in the pharmaceutical industry. Peptides, defined by the FDA as biopolymers ...

Exenatide is a generic prescription drug approved to help manage blood sugar levels in adults with type 2 diabetes. It’s not available in a brand-name version. Exenatide comes as a liquid solution ...

Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. The finding contrasts with positive results from previous phase II studies ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest trial ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other conditions with newer weight-loss drugs. By Gina Kolata The idea was so ...

Vivani Medical has commenced the first-in-human, randomised trial, LIBERATE-1, by initiating screening and enrolment to assess the pharmacokinetic and safety profile of its exenatide NanoPortal drug ...